Drug Trial Radar · NCT01011660
Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients
Last checked: Nov 19, 2026Latest source record: Aug 13, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
13,542
Planned (sponsor's estimate)
Start
Oct 2007
Primary completion
Aug 2012
Study completion Dec 2012
Sponsor
- Lead sponsor
- Chinese Academy of Medical Sciences, Fuwai HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 11, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to investigate the optimized treatment strategy of hypertension, so as to make more patients to reach the blood pressure goals and to reduce cardio-cerebrovascular events. Objective and Methods: Patients are eligible for inclusion in the study if they are essential hypertension, 50-79 years of age with at least one cardiovascular risk factor and sign the informed consent forms. This project is a multi-centre, prospective randomized,,openlabel blind-endpoint evaluation controlled (PROBE) trial. 12000 patients will be randomly assigned to either of low-dose Amlodipine+Telmisartan group or Amlodipine+ diuretics group. Among those patients with serum cholesterol between 4.0-6.1mmol/L, they will be also randomized into small dose of statin-based regimen or standard management regimen; Patients will also randomly assigned to intensive lifestyle intervention group or standard intervention group according to the community area where the patients in.
Conditions
- Essential Hypertension
Interventions
Amlodipine, Telmisartan, Amiloride Compound , SimvastatinDrug
Amlodipine; Telmisartan; Amiloride Compound; Simvastatin
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary study outcomes are composite of non-fatal stroke, non-fatal myocardial infarction and cardiovascular death.Time frame: 3-4 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Wang Wen
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.